Jeena Sikho Lifecare Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 Approval of Clinical Trial of Anti-Diabetes Efficacy of SDM02 TABLETS, Shuddhi XS Syrup, Petshuddhi Churna and Shuddhi Dr. B P Care tablets.'.
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jeena Sikho Lifecare Limited has received approval to conduct clinical trials for the anti-diabetes efficacy of four of its products: SDM02 Tablets, Shuddhi XS Syrup, Petshuddhi Churna, and Shuddhi Dr. B P Care Tablets. The intimation was filed under Regulation 30 of SEBI (LODR) Regulations, 2015. This marks a regulatory milestone for the company's healthcare and Ayurvedic product portfolio. Clinical trial approval allows the company to formally test and validate the therapeutic claims of these products.
Positive for shareholders — successful clinical trials could open a new anti-diabetes segment, expanding the company's addressable market and supporting future revenue growth. Short-term stock reaction may be modest as clinical trials typically take time to deliver results.